“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.

Slides:



Advertisements
Similar presentations
UGA Doctor of Pharmacy Candidate
Advertisements

Role of the Pharmacist in Collaborative Care for Mental Health and Addiction Treatment in Medically Underserved Appalachia Sarah T. Melton, PharmD,BCPP,CGP.
Connecting Muslims to Coverage AMHP Where Faith and Healthy Communities Come Together.
Context and Overview of Recommended Actions to Reduce Psychiatric Readmissions Michael Trangle, MD Associate Medical Director, Behavioral Health Division.
Best Practices in Mental Health Services in Nursing Homes Steve Bartels, MD, MS President, American Association for Geriatric Psychiatry.
Depression—There are at least two sides to every story.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
The Future of Health Care for Older People: Will the Disadvantaged by Left Behind? Chad Boult, MD, MPH, MBA Professor and Director Lipitz Center for Integrated.
Prescription Drug Abuse and Misuse in the Elderly Thomas L. Patterson, Ph.D. Support for this work: NIMH Center Grants P30 MH49693 and MH45131, and by.
INTRODUCTION Polypharmacy and Distinctive Demographics of Congestive Heart Failure Patients Seenu Abraham 1, Peter Vayalil 1, Sagar Patel 1, Tim Quinn.
Patient Compliance With Medical Advice. Patient compliance (patient adherence) :  The extent to which the patient adheres to medical advice Patient compliance.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
Prevalence of Predictors of Antidepressant Prescribing in Nursing Home Residents in the United States Swapna U. Karkare, MS, Sandipan Bhattacharjee, MS,
Out-of-pocket healthcare expenditures for cancer patients in the United States: Findings from the Medical Expenditure Panel Survey Lisa M. Lines, MPH 1,2.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care Trends in the.
Managing Warfarin Drug Interactions: The Bayview Experience DAWN Users Group, November 2002 Charles H. Twilley, MBA, PharmD Johns Hopkins Bayview Medical.
Who Are We? Molecular Testing Labs is a cutting-edge molecular and genetics testing laboratory focused on pharmacogenomics. Our primary goal is to provide.
Sales Trainer for PGXL Laboratories
Maryland Cancer Plan Pain Management Committee Suzanne A Nesbit, PharmD, BCPS Clinical Coordinator, Cancer Pain Service Sidney Kimmel Comprehensive Cancer.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
Implementing pharmacogenetics with CIPHER™ Personalized Medicine Program Property of PGxl Laboratories Kristen K. Reynolds, PhD VP Laboratory Operations.
The Business Case for Bidirectional Integrated Care: Mental Health and Substance Use Services in Primary Care Settings and Primary Care Services in Specialty.
Web Prevention Early intervention Improved outcomes More effective management of chronic disease.
HRET/K-HEN Readmissions Race Office Hour Building a Multidisciplinary Care Transitions Team January 25, 2013.
The University of Mississippi Medical Center
5 th Annual Lourdes Cardiology Services Symposium: Cardiology for Primary Care.
Snapshot of IMS LifeLink Claims Database 10% Random Sample
IF:Pain © PGXL Laboratories. Pain Management - Opioids Problem and Implications 2% to 40% of adults suffer from chronic pain 1 90% of patients.
Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.
“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance.
Foot and Ankle Specialist practicing for over 30 years in the Hudson Valley. Operates six successful practices in the New York Market. His passion has.
Simon Belderbos Consultant Psychiatrist
1 Cost-Sharing: Effects on Spending and Outcomes Briefing by Katherine Swartz, PhD Harvard School of Public Health February 3, 2011.
1 The Patient Perspective: Satisfaction Survey Presented at: Disease Management Colloquium June 22, 2005 Shulamit Bernard, RN, PhD.
Community Pharmacy Adherence Services. Adherence to Prescription Medication Many patients have difficulty taking prescription medications as prescribed.
如何讓用藥更安全 台大藥學系 林慧玲. Medication-Use System Errors resulted in ADEs Intercepted Physician prescribing56%48% Transcription/verification6%33% Pharmacy dispensing4%34%
DataBrief: Did you know… DataBrief Series ● February 2013 ● No. 38 Medicare Spending for Beneficiaries with Severe Mental Illness and Substance Use Disorder.
Polypharmacy May 2008 CRIT Heidi Auerbach, MD Copyright Boston University Medical Center.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Depression Care Management Lessons from Project IMPACT _____________________________________________________ Jürgen Unützer, MD, MPH Professor and Vice.
Chronic Illness and Older Adults
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Healthcare Delivery System Foundation Standard Understand the healthcare delivery system (public, private, government and non-profit)
Urine Drug Monitoring: Indiana Council of Community Mental Health Centers Jerry Vaccaro, M.D. President, Ingenuity Health October 15, 2015.
Optimization of psychotropic drug prescription in nursing home patients with dementia: the PROPER study (PRescription Optimization of Psychotropic drugs.
Pharmacogenetics.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
How Genetic Variants Impact the Safety and Effectiveness of Drugs Pharmacogenetics © PGXL Laboratories.
Terry McInnis, MD MPH President- Blue Thorn, Inc - Mobile Co-Chair- Center for.
Pharmacogenomics: Improving the Dynamic of Care in Medication Management 1.
Managed Care: Your Population N226 Winter 2003 Professor: Joanne Spetz 5 February 2003.
Polypharmacy in a Patient Centered Medical Home Carilion Clinic – VTC Family Medicine Roanoke, Virginia.
Electronic Medical Records: Is It Working in Long Term Health Care? Krista Phillips, SRNA Chris Wheeler, SRNA Josh Campbell, SRNA Alberto Coustasse, MD,
Aging, Health and Mental Health Prepared for distribution by the CSWE Gero-Ed Center.
EVALUATING THE EFFECTIVENESS OF THE AGS UPDATED 2012 BEERS CRITERIA AS AN EDUCATIONAL TOOL IN A FAMILY MEDICINE RESIDENCY TRAINING PROGRAM Eseoghene Abokede.
Using an EHR Template and the Beer’s List to Address Geriatric Polypharmacy Rose Family Medicine Residency Emily Gutgsell, MD Emma Bjore, MD Anna Plunkett,
Comorbidity and Multimorbidity: Measurement and Interventions Holly M. Holmes, MD, MS Dept of General Internal Medicine.
Community Education Promoting Informed Medicine Use.
Depression in chronic kidney disease 신장내과 R4 정우진 Mini topic.
Care Transitions for Medication Safety in the Community
Treatment Access A Substance Use Disorder Perspective
Drug Therapy in Geriatric Patients
Don’t Nudge Me: The Limits of Behavioral Economics in Medicine
Healthcare Delivery System
Information for Network Providers
68.3 million errors (28% of total) cause moderate or serious harm
New Opportunities in Medicare
Treatment and Management of Suicide Risk: Available Treatments
The ABCs of Pharmacogenomics in Clinical Practice
Social Aspects in Psychosomatic
Presentation transcript:

“Empowerment At The Source of Treatment” Psychotropic & Unnecessary Medication Reduction: Rethinking Your Pathway To compliance

“Empowerment At The Source of Treatment” Statistics to Consider Medicare Prescriptions: 198 million in 2010 – for behavioral medications annual increase rate of (9.3% est.) 992 million in 2010 – for all medications Adverse Drug Reactions: 2.2 million annually 76% of hospitalized patients 106,000 deaths annually Cost to health US health system - $136B annually Re-Hospitalization: 22% of behavioral patients 24% of cardiovascular patients 74% are on more than 3 medications Drug Label Warnings for Pharmacogenomics: 190+ medications

“Empowerment At The Source of Treatment” Factors to Consider 1. Cost 100% covered by Medicare (facility pay $0) Covered by most all Private Insurances No Balance Billing to Patients 2. What is your plan/program for Reduction of Unnecessary Meds and Overuse of Psych Medication –compliance? 3. Extending Patient Independence, Mobility, Cognitive Responses, etc. – profitability

“Empowerment At The Source of Treatment” What is Pharmacogenomics ?

“Empowerment At The Source of Treatment” CYP450 Metabolizer Phenotypes Extensive (EM) : Normal metabolism Ultrarapid (UM) : Rapid rate of metabolism Intermediate (IM) : Reduced rate of metabolism Poor (PM) : Slow rate of metabolism

“Empowerment At The Source of Treatment” -Elderly patients on average receive 4-10x as many medications as the normal healthy population -Elderly patients are more sensitive to the side effects of medications -Elderly patients are dealing with more chronic health conditions -Consequences of side effects and adverse events carry greater morbidity and mortality in the elderly Metabolic Validation Testing & Geriatrics

“Empowerment At The Source of Treatment” Tolerability of Psychiatric Medication Side effects and patient frustration Cost of medications Suboptimal drug regimens 1 “Trial and error” prescribing Each additional provider prescribing medications increased odds of an adverse drug event by 29% 2 1 New England Healthcare Institute (NEHI). Thinking Outside the Pillbox: A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease.August Green JL et al. Am J Geriatr Pharmacoghter Mar;5(1):31-39.

“Empowerment At The Source of Treatment” Compare Cost of Treating with Testing, vs. Traditional Trial and Error Behavior Health Medications 65% of MDD patients fail their initial medication trial ≥ 75% fail to respond to subsequent medication trials Non-responders cost 2.5 times more overall than responders 1 $17, 128/yr vs. $6,770/yr Direct medical costs are 2.5 times higher for non-responders 1 $12,155/yr vs. $5,755/yr 1. Social and economic burden of treatment-resistant major depressive disorder: A comprehensive, systematic analysis of the literature, Mrazek et al (Submitted). 2. Psychiatric pharmacogenomics predict health resource utilization of outpatients with anxiety and depression in a staff model health maintenance organization, Winner et al (Submitted).

“Empowerment At The Source of Treatment” What Genes can be Tested? 2D6 2C9 2C19 1A2 3A4 3A5 SLC01B1 HTR2C OPRM1 COMT Factor II Factor V MTHFR VKORC1 SERT NET FITR2A ABCB1 ADRA2A What Panels can be Reported? Pain Depression Psychiatric Anxiety Cardiology Thrombophilia Anti Coagulants ADHD

“Empowerment At The Source of Treatment” Assisted/Skilled Living Center Pilot Program

“Empowerment At The Source of Treatment” Statistical Overview Residents Tested: 132 On Avoid Use Meds: 23% Need Dosage Review: 48% Drug-Drug Warning: 48%

“Empowerment At The Source of Treatment” Contact Information Clay Bullard President, PGx Medical (405)